Answers are grounded in this paper and cite their sources.
Review highlights P2Y12 inhibitor monotherapy after brief dual antiplatelet therapy in coronary stent patients, suggesting an alternative post-intervention strategy.
P2Y12 inhibitor monotherapy after dual antiplatelet therapy (DAPT; a P2Y12 inhibitor plus aspirin) for a brief duration has recently emerged as an attractive alternative for patients undergoing percutaneous coronary intervention (PCI) with a drug-eluting stent.
No takes yet. Share an insight, caveat, or question.
Min et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: